Fequesetide(Cat No.:I044296)is a synthetic peptide inhibitor designed to disrupt the interaction between programmed death-ligand 1 (PD-L1) and its receptor PD-1, a key immune checkpoint involved in tumor immune evasion. By blocking this interaction, Fequesetide enhances T-cell activation and promotes anti-tumor immune responses, making it a promising candidate in cancer immunotherapy research. As a peptide-based molecule, it offers potential advantages such as improved tissue penetration and reduced immunogenicity compared to monoclonal antibodies. Fequesetide is utilized in preclinical studies exploring immune checkpoint blockade strategies and the development of novel anti-cancer therapeutics.